Belmont, MA, United States of America

Tianjun Zhou

This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tianjun Zhou. Retrieved from https://idiyas.com/inventor/tianjun-zhou-gvfpdg4b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Tianjun Zhou

Introduction

Tianjun Zhou is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the area of kinase inhibition. His work focuses on developing compounds that can effectively modulate kinase activity, which is crucial for treating various diseases.

Latest Patents

Tianjun Zhou holds a patent for "Heteroaryl compounds for kinase inhibition." This patent describes compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity. The patent also outlines methods of treatment for diseases associated with these kinase activities.

Career Highlights

Zhou is currently employed at Takeda Pharmaceutical Company Limited, where he continues to innovate and contribute to the development of new therapeutic solutions. His expertise in kinase modulation has positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Wei-Sheng Huang and Yongjin Gong. Their collaborative efforts have further advanced the research and development of kinase inhibitors.

Conclusion

Tianjun Zhou's work exemplifies the impact of innovative research in the pharmaceutical field. His contributions to kinase inhibition are paving the way for new treatments and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…